RESUMEN
BACKGROUND: Human papillomavirus (HPV) has been identified as an etiopathogenetic factor in oropharyngeal squamous cell carcinoma. The HPV E6 and E7 oncogenes are instrumental in promoting proliferation and blocking differentiation leading to tumorigenesis. Although surgical intervention can remove such tumors, the potential for an etiologic field effect with recurrent disease is real. A downstream effector of E7 oncoprotein, enhancer of zeste homolog 2 (EZH2), is known to promote proliferation and to pose a block in differentiation and in turn, could lead to HPV-induced malignant transformation. However, the EZH2 pathway is amenable to low toxicity therapies designed to promote differentiation to a more benign state and prevent recurrent disease by inhibiting the incorporation of HPV into the genome. This is the first study using clinical specimens to demonstrate EZH2 protein expression in oropharyngeal carcinoma (OPC). METHODS: The study included eight patients with oropharyngeal carcinoma, confirmed p16INK4a- positive by immunohistochemistry (IHC). The tissue expression of E6/E7 messenger RNA (mRNA) was measured by RNAscope® in-situ hybridization technology. Expression of EZH2, Ki-67, and mitotic indices were assessed by morphoproteomic analysis. Biomedical analytics expanded the results with data from Ingenuity Pathway Analysis (IPA) and KEGG databases to construct a molecular network pathway for further insights. RESULTS: Expression of E6 and E7 oncogenes in p16INK4a- positive oropharyngeal carcinoma was confirmed. EZH2 and its correlates, including elevated proliferation index (Ki-67) and mitotic progression were also present. Biomedical analytics validated the relationship between HPV- E6 and E7 and the expression of the EZH2 pathway. CONCLUSION: There is morphoproteomic and mRNA evidence of the association of p16INK4a-HPV infection with the E6 and E7 oncogenes and the expression of EZH2, Ki-67 and mitotic progression in oropharyngeal carcinoma. The molecular network biology was confirmed by biomedical analytics as consistent with published literature. This is significant because the biology lends itself to targeted therapeutic options using metformin, curcumin, celecoxib and sulforaphane as therapeutic strategies to prevent progression or recurrence of disease.
Asunto(s)
Regulación Neoplásica de la Expresión Génica , Terapia Molecular Dirigida/métodos , Proteínas Oncogénicas Virales/genética , Neoplasias Orofaríngeas/virología , Proteínas E7 de Papillomavirus/genética , Proteínas Represoras/genética , Anciano , Biopsia con Aguja , Proteína Potenciadora del Homólogo Zeste 2/genética , Femenino , Humanos , Inmunohistoquímica , Hibridación in Situ/métodos , Masculino , Neoplasias Orofaríngeas/tratamiento farmacológico , Neoplasias Orofaríngeas/patología , Papillomaviridae/genética , Papillomaviridae/patogenicidad , Infecciones por Papillomavirus/tratamiento farmacológico , Infecciones por Papillomavirus/genética , Infecciones por Papillomavirus/patología , Pronóstico , Proteómica , ARN Mensajero/metabolismo , Muestreo , Resultado del Tratamiento , Infecciones Tumorales por Virus/tratamiento farmacológico , Infecciones Tumorales por Virus/genética , Infecciones Tumorales por Virus/patologíaRESUMEN
Cervix carcinoma is an important health problem world-wide, being the second most common cancer among women, ranking first in many developing countries. A number of important epidemiological risk factors have been identified as contributing to the development of CIN and invasive cervix carcinoma. Of key importance is infection with human papillomavirus (HPV), which is the primary risk factor. There are evolving primary and secondary preventive strategies that could further reduce the burden from cervical carcinoma. The possible primary preventive strategies include risk reduction, diet or dietary supplements, HPV vaccines, and other chemopreventive agents. The possible advances in secondary preventive strategies include new technologies for Pap smears, HPV typing triage, and other adjuvant screening procedures. The impact of these strategies will depend upon evidence to support their use along with the characteristics of the population and environment in which they are used.
Asunto(s)
Anticarcinógenos/uso terapéutico , Antioxidantes/uso terapéutico , Carcinoma de Células Escamosas/prevención & control , Neoplasias del Cuello Uterino/prevención & control , Vitaminas/uso terapéutico , Ácido Ascórbico/uso terapéutico , Carcinoma de Células Escamosas/epidemiología , Carcinoma de Células Escamosas/etiología , Carcinoma de Células Escamosas/metabolismo , Carcinoma de Células Escamosas/virología , Ensayos Clínicos como Asunto , Colposcopía/métodos , Dieta , Femenino , Ácido Fólico/uso terapéutico , Humanos , Procesamiento de Imagen Asistido por Computador , Tamizaje Masivo/métodos , Necesidades Nutricionales , Prueba de Papanicolaou , Papillomaviridae/genética , Papillomaviridae/aislamiento & purificación , Papillomaviridae/patogenicidad , Infecciones por Papillomavirus/epidemiología , Infecciones por Papillomavirus/genética , Infecciones por Papillomavirus/patología , Fotoquimioterapia , Factores de Riesgo , Infecciones Tumorales por Virus/epidemiología , Infecciones Tumorales por Virus/genética , Infecciones Tumorales por Virus/patología , Displasia del Cuello del Útero/epidemiología , Displasia del Cuello del Útero/virología , Displasia del Cuello del Útero/etiología , Displasia del Cuello del Útero/metabolismo , Displasia del Cuello del Útero/prevención & control , Neoplasias del Cuello Uterino/epidemiología , Neoplasias del Cuello Uterino/etiología , Neoplasias del Cuello Uterino/metabolismo , Neoplasias del Cuello Uterino/virología , Frotis Vaginal/instrumentación , Frotis Vaginal/métodos , Vacunas Virales , Vitamina E/uso terapéutico , beta Caroteno/uso terapéuticoRESUMEN
Human cervical carcinoma cell lines that harbor human papilloma virus (HPV) have been reported to express HPV E6 and E7 proteins at least in the beginning stages if not at all stages of the disease. The HPV E6 and E7 proteins bind to and inactivate the products of the p53 and retinoblastoma (Rb) tumor suppressor genes, which thereby allow the cervical carcinoma cells to circumvent the action of these tumor suppressor genes. We observed that the introduction of the antisense HPV 18 E6 and E7 sequences, as well as a sense cDNA for the human wild-type Rb gene into a human cervical carcinoma cell line (HeLa), which is positive for the HPV 18 provirus, decreased the in vitro and in vivo growth rate of the transfected cells if both antisense transcripts for the HPV 18 E6 and E7 and sense transcripts for human Rb were expressed. In addition, overexpression of a complementary DNA (cDNA) for the Rb messenger RNA was sufficient to slow the proliferation of HeLa cells, and the level of Rb cDNA expression was correlated with the degree to which the rate of growth of the tumor was slowed. The results of our experiments show that the presence of HPV E6 and E7 proteins and the resultant inactivation of Rb in cervical carcinoma cells contributes to the neoplastic phenotype even in highly evolved cervical carcinoma cell lines such as HeLa, which have been derived from a cervical carcinoma patient at an advanced stage of the disease process. These data suggest that the HPV proteins play a role not only at the beginning of cervical cancer, but also at advanced stages of this disease. These experiments may lead to genetic approaches to the control of this disease that involve antisense sequences that downregulate the E6 and E7 genes or lead to expression of the Rb gene.
Asunto(s)
Carcinoma de Células Escamosas/virología , Transformación Celular Viral/genética , Proteínas de Unión al ADN , Genes de Retinoblastoma , Células HeLa/efectos de los fármacos , Proteínas Oncogénicas Virales/antagonistas & inhibidores , Papillomaviridae/genética , Infecciones por Papillomavirus/genética , ARN sin Sentido/farmacología , ARN Mensajero/farmacología , Proteína de Retinoblastoma/antagonistas & inhibidores , Infecciones Tumorales por Virus/genética , Neoplasias del Cuello Uterino/virología , Animales , Secuencia de Bases , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patología , División Celular/efectos de los fármacos , Citomegalovirus/genética , ADN Complementario/genética , ADN Viral , Femenino , Regulación Viral de la Expresión Génica , Vectores Genéticos , Células HeLa/virología , Humanos , Ratones , Ratones Desnudos , Datos de Secuencia Molecular , Virus de la Leucemia Murina de Moloney/genética , Trasplante de Neoplasias , Proteínas Oncogénicas Virales/genética , Proteínas Oncogénicas Virales/fisiología , Papillomaviridae/aislamiento & purificación , Papillomaviridae/patogenicidad , Papillomaviridae/fisiología , Infecciones por Papillomavirus/virología , Reacción en Cadena de la Polimerasa , Regiones Promotoras Genéticas , Proteína de Retinoblastoma/genética , Transfección , Infecciones Tumorales por Virus/virología , Neoplasias del Cuello Uterino/genética , Neoplasias del Cuello Uterino/patología , Dedos de ZincRESUMEN
We have investigated the diversity of a hypervariable segment of the human papillomavirus type 16 (HPV-16) genome among 301 virus isolates that were collected from 25 different ethnic groups and geographic locations. Altogether, we distinguished 48 different variants that had diversified from one another along five phylogenetic branches. Variants from two of these branches were nearly completely confined to Africa. Variants from a third branch were the only variants identified in Europeans but occurred at lower frequency in all other ethnic groups. A fourth branch was specific for Japanese and Chinese isolates. A small fraction of all isolates from Asia and from indigenous as well as immigrant populations in the Americas formed a fifth branch. Important patterns of HPV-16 phylogeny suggested coevolution of the virus with people of the three major human races, namely, Africans, Caucasians, and East Asians. But several minor patterns are indicative of smaller bottlenecks of viral evolution and spread, which may correlate with the migration of ethnic groups in prehistoric times. The colonization of the Americas by Europeans and Africans is reflected in the composition of their HPV-16 variants. We discuss arguments that today's HPV-16 genomes represent a degree of diversity that evolved over a large time span, probably exceeding 200,000 years, from a precursor genome that may have originated in Africa. The identification of molecular variants is a powerful epidemiological and phylogenetic tool for revealing the ancient spread of papillomaviruses, whose trace through the world has not yet been completely lost.